Allogene Therapeutics
ALLO
170 hedge funds and large institutions have $201M invested in Allogene Therapeutics in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 61 increasing their positions, 37 reducing their positions, and 16 closing their positions.
150% more call options, than puts
Call options by funds: $120K | Put options by funds: $48K
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
65% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 37
8% more funds holding
Funds holding: 158 → 170 (+12)
3% less capital invested
Capital invested by funds: $208M → $201M (-$6.87M)
10.89% less ownership
Funds ownership: 83.95% → 73.06% (-11%)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.43M |
| 2 |
Millennium Management
New York
|
+$2.25M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.11M |
| 4 |
Two Sigma Investments
New York
|
+$2.11M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$12.6M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$12.5M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$12.4M |
| 4 |
Goldman Sachs
New York
|
-$5.13M |
| 5 |
FCMV
Foresite Capital Management VI
Larkspur,
California
|
-$3.25M |
ALLO Hedge Fund Activity: Q3 2025 in Review
170 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2025, worth a combined $201M — down 3.3% from $208M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ALLO positions and 16 closed out — a net gain of 14 holders — while 61 added to existing stakes and 37 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.43M. The largest seller was Capital World Investors, exiting entirely with an estimated $12.6M sold.
- 170 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2025, up from 158 in Q2 2025.
- Funds reported $201M of Allogene Therapeutics stock for Q3 2025, down 3.3% quarter-over-quarter.
- 30 funds opened new Allogene Therapeutics positions in Q3 2025 and 16 closed out, a net change of +14 holders.
- The largest Allogene Therapeutics buyer in Q3 2025 was Citadel Advisors, an estimated $4.43M added.
- The largest Allogene Therapeutics seller in Q3 2025 was Capital World Investors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2025.